MESO · NASDAQ
Mesoblast Limited
$14.37 +0.79 (+6.42%)
Company overview
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.9B
- Employees
- 73
- Headquarters
- Melbourne, VIC
- Website
- mesoblast.com
- CEO
- Silviu Itescu
- Listed
- January 20, 2010
- P/E
- -17.11
- Dividend yield
- 0.00%
Company financials
- Revenue
- $17.2M
- Gross profit
- -$35.9M
- Operating income
- -$110M
- EBITDA
- -$58.2M
- Net income
- -$102M
- EPS
- -$0.84
- Total assets
- $782M
- Total debt
- $135M
- Gross margin
- -208.50%
- Net margin
- -593.92%
- Earnings yield
- -5.85%
No product segmentation.
Showing FY 2020
MESO
1D
NASDAQ
O13.24H13.37L13.19C13.36+0.18 (+1.37%)Vol23.85K